These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Rationale and design of the OPTIMIZE trial: OPen label multicenter randomized trial comparing standard IMmunosuppression with tacrolimus and mycophenolate mofetil with a low exposure tacrolimus regimen In combination with everolimus in de novo renal transplantation in Elderly patients. de Boer SE; Sanders JSF; Bemelman FJ; Betjes MGH; Burgerhof JGM; Hilbrands L; Kuypers D; van Munster BC; Nurmohamed SA; de Vries APJ; van Zuilen AD; Hesselink DA; Berger SP BMC Nephrol; 2021 Jun; 22(1):208. PubMed ID: 34078323 [TBL] [Abstract][Full Text] [Related]
7. Regulatory T cells for minimising immune suppression in kidney transplantation: phase I/IIa clinical trial. Roemhild A; Otto NM; Moll G; Abou-El-Enein M; Kaiser D; Bold G; Schachtner T; Choi M; Oellinger R; Landwehr-Kenzel S; Juerchott K; Sawitzki B; Giesler C; Sefrin A; Beier C; Wagner DL; Schlickeiser S; Streitz M; Schmueck-Henneresse M; Amini L; Stervbo U; Babel N; Volk HD; Reinke P BMJ; 2020 Oct; 371():m3734. PubMed ID: 33087345 [TBL] [Abstract][Full Text] [Related]
11. Immunosuppression Has Long-Lasting Effects on Circulating Follicular Regulatory T Cells in Kidney Transplant Recipients. Niu Q; Mendoza Rojas A; Dieterich M; Roelen DL; Clahsen-van Groningen MC; Wang L; van Gelder T; Hesselink DA; van Besouw NM; Baan CC Front Immunol; 2020; 11():1972. PubMed ID: 32983131 [No Abstract] [Full Text] [Related]
12. Low-dose Thymoglobulin vs Basiliximab Induction Therapy in Low-Risk Living Related Kidney Transplant Recipients: A Prospective Randomized Trial. Martinez-Mier G; Moreno-Ley PI; Budar-Fernández LF; Méndez-López MT; Allende-Castellanos CA; Jiménez-López LA; Barrera-Amoros DA; Aguilar-Sandoval E; De la Paz-Román M; Soto-Miranda E; Rivera-Sanchez Y; Martínez-Maldonado M Transplant Proc; 2021 Apr; 53(3):1005-1009. PubMed ID: 32178925 [TBL] [Abstract][Full Text] [Related]
13. Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients. Hill P; Cross NB; Barnett AN; Palmer SC; Webster AC Cochrane Database Syst Rev; 2017 Jan; 1(1):CD004759. PubMed ID: 28073178 [TBL] [Abstract][Full Text] [Related]
14. Kidney transplantation: a safe step forward for regulatory immune cell therapy. Thomson AW; Tevar AD Lancet; 2020 May; 395(10237):1589-1591. PubMed ID: 32446400 [No Abstract] [Full Text] [Related]
15. Antibody induction versus placebo, no induction, or another type of antibody induction for liver transplant recipients. Penninga L; Wettergren A; Wilson CH; Chan AW; Steinbrüchel DA; Gluud C Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD010253. PubMed ID: 24901467 [TBL] [Abstract][Full Text] [Related]
16. Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipients. Wagner M; Earley AK; Webster AC; Schmid CH; Balk EM; Uhlig K Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD007746. PubMed ID: 26633102 [TBL] [Abstract][Full Text] [Related]
17. Minimization of immunosuppressive therapy and immunological monitoring of kidney transplant recipients with long-term allograft survival. Pretagostini R; Cinti P; Lai Q; Poli L; Berloco PB Transpl Immunol; 2008 Nov; 20(1-2):3-5. PubMed ID: 18773959 [TBL] [Abstract][Full Text] [Related]
18. Cordyceps sinensis (a traditional Chinese medicine) for kidney transplant recipients. Hong T; Zhang M; Fan J Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD009698. PubMed ID: 26457607 [TBL] [Abstract][Full Text] [Related]
19. Feasibility, long-term safety, and immune monitoring of regulatory T cell therapy in living donor kidney transplant recipients. Harden PN; Game DS; Sawitzki B; Van der Net JB; Hester J; Bushell A; Issa F; Brook MO; Alzhrani A; Schlickeiser S; Scotta C; Petchey W; Streitz M; Blancho G; Tang Q; Markmann J; Lechler RI; Roberts ISD; Friend PJ; Hilton R; Geissler EK; Wood KJ; Lombardi G Am J Transplant; 2021 Apr; 21(4):1603-1611. PubMed ID: 33171020 [TBL] [Abstract][Full Text] [Related]
20. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial. Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]